Original Literature | Model OverView |
---|---|
Publication
Title
When signaling pathways collide: positive and negative regulation of toll-likereceptor signal transduction.
Affiliation
School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2,Ireland. laoneill@tcd.ie
Abstract
Toll-like receptor (TLR) signaling is subjected to crosstalk from other signals,with a resulting positive or negative effect. There is complex crosstalk betweenthe NLR family of immune-regulatory molecules and TLRs, and C-type lectinreceptors such as Dectin-1 synergize with TLR2 via the tyrosine kinase Syk.Bruton's tyrosine kinase plays an important positive role in TLR signaling,whereas the TAM family of receptor tyrosine kinases is inhibitory. The tyrosinephosphatase SHP1 has been shown to positively regulate induction ofinterferon-beta, whereas SHP2 inhibits the kinase TBK1, limiting this response.K63-linked polyubiquination has also been shown to be critical for theinitiation of TLR signaling. Finally, glucocorticoids affect TLR signaling byinducing the phosphatase MKP1 and inhibiting TBK1 activation. These recentfindings emphasize the importance of considering TLR signaling in the context ofother signaling pathways, as is likely to occur in vivo during infection andinflammation.
PMID
18631453
|
Entity
Process
p38
--
MO000000022
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m20
10
infinite
0
TRANSPATH | MO000000022 |
--
NF-kappaB
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m5
10
infinite
0
TRANSPATH | MO000000058 |
--
PLCgamma {activated}
--
MO000000102
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m119
10
infinite
0
TRANSPATH | MO000000102 |
--
TRAF6
--
MO000000212
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m183
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
IkappaB-alpha{p}
--
MO000000220
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m190
10
infinite
0
TRANSPATH | MO000000220 |
--
IkappaB-alpha
--
MO000000233
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m199
10
infinite
0
InterPro | IPR002110 |
TRANSPATH | MO000000233 |
--
Btk
--
MO000001935
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m367
10
infinite
0
InterPro | IPR001452 |
TRANSPATH | MO000001935 |
--
IRF-3
--
MO000007694
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m977
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
IRAK-2
--
MO000016566
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1569
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016566 |
--
MyD88
--
MO000016573
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1572
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000016573 |
--
TAB1
--
MO000016588
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1583
10
infinite
0
InterPro | IPR001932 |
TRANSPATH | MO000016588 |
--
IKK-gamma
--
MO000016599
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m1593
10
infinite
0
InterPro | IPR007087 |
TRANSPATH | MO000016599 |
--
p50:RelA-p65
--
MO000016632
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1617
10
infinite
0
TRANSPATH | MO000016632 |
--
PKCepsilon
--
MO000016645
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m1629
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016645 |
--
IFN Type I
--
MO000016658
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1634
10
infinite
0
TRANSPATH | MO000016658 |
--
IKK-alpha:IKK-beta:IKK-gamma
--
MO000016661
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m1637
10
infinite
0
TRANSPATH | MO000016661 |
--
Caspase-1{activated}
--
MO000016828
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1765
10
infinite
0
TRANSPATH | MO000016828 |
--
SHP-1
--
MO000016884
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1805
10
infinite
0
InterPro | IPR000242 |
TRANSPATH | MO000016884 |
--
SHP-2
--
MO000016886
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1807
10
infinite
0
InterPro | IPR000242 |
TRANSPATH | MO000016886 |
--
IL-10
--
MO000017247
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2103
10
infinite
0
InterPro | IPR000098 |
TRANSPATH | MO000017247 |
--
cytokines
--
MO000019387
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m3957
10
infinite
0
TRANSPATH | MO000019387 |
--
proIL-1beta
--
MO000019449
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m4012
10
infinite
0
InterPro | IPR003297 |
TRANSPATH | MO000019449 |
--
protein remnants
--
MO000019479
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m360980
10
infinite
0
TRANSPATH | MO000019479 |
--
NADPH oxidase
--
MO000021432
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m5783
10
infinite
0
TRANSPATH | MO000021432 |
--
glucocorticoids
--
MO000021732
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m6069
10
infinite
0
TRANSPATH | MO000021732 |
--
TAB2
--
MO000022125
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m6433
10
infinite
0
TRANSPATH | MO000022125 |
--
p50:RelA-p65{pS}
--
MO000033294
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m11984
10
infinite
0
TRANSPATH | MO000033294 |
--
IRF-3{p}
--
MO000041456
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19324
10
infinite
0
TRANSPATH | MO000041456 |
--
TLR9: TLR9
--
MO000042012
cso30:c:Complex
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m19828
10
infinite
0
TRANSPATH | MO000042012 |
--
PANX1
--
MO000064988
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m39857
10
infinite
0
TRANSPATH | MO000064988 |
--
GRIP1
--
MO000074564
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m49366
10
infinite
0
TRANSPATH | MO000074564 |
--
Nalp3
--
MO000116924
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m86033
10
infinite
0
TRANSPATH | MO000116924 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
TRAF6 {activated}
--
e100
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m104
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
ligand: TAM: IFNAR1
--
e101
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m105
0
infinite
0
--
Lyn {activated}
--
e104
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m109
10
infinite
0
InterPro | IPR001452 |
TRANSPATH | MO000000144 |
--
CpG motif: TLR9: TLR9: Btk
--
e105
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m110
0
infinite
0
--
LPS: TLR4: Btk
--
e106
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m111
0
infinite
0
--
LPS: TLR4: MAL{pY86, pT106}: MyD88: SOCS1
--
e107
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m112
0
infinite
0
--
LPS: TLR4: MAL{pY86, pT106}: MyD88
--
e108
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m113
0
infinite
0
--
LPS: TLR4: MyD88: SOCS1
--
e109
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m114
0
infinite
0
--
TLR ligand: TLR: TLR: MyD88
--
e11
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m12
0
infinite
0
--
ligand: TRME-1: DAP12
--
e110
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m115
0
infinite
0
--
ligand: TRME-1: DAP12{pY}
--
e111
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m116
0
infinite
0
--
ligand: TRME-1: DAP12{pY}: p85:p110
--
e112
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m117
0
infinite
0
--
ligand: TRME-1: DAP12{pY}: PLCgamma
--
e113
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m118
0
infinite
0
--
cytokine
--
e114
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m120
0
infinite
0
--
antibody
--
e115
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m121
0
infinite
0
--
antibody: TLR4
--
e116
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m122
0
infinite
0
--
CD32A
--
e117
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m123
0
infinite
0
--
antibody: TLR4: CD32A
--
e118
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m124
0
infinite
0
--
PI3K {activated}
--
e119
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m126
10
infinite
0
TRANSPATH | MO000000030 |
--
LPS: TLR4
--
e12
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m13
0
infinite
0
--
AKT {activated}
--
e120
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m129
10
infinite
0
TRANSPATH | MO000000048 |
--
TAM
--
e122
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m131
0
infinite
0
--
Gas6: TAM
--
e123
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m132
0
infinite
0
--
Axl: IFNAR1
--
e124
cso30:c:Complex
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m133
0
infinite
0
--
Gas6: TAM: Axl:IFNAR1
--
e125
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m134
0
infinite
0
--
STAT1 {activated}
--
e126
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m135
10
infinite
0
InterPro | IPR008967 |
TRANSPATH | MO000013119 |
--
TLR ligand: TLR: TLR: MyD88: IRAK-1{p}: SHP-1: IRAK-2: IRAK-4
--
e127
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m136
0
infinite
0
--
TLR ligand: TLR: TLR: MyD88: IRAK-4
--
e128
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m137
0
infinite
0
--
type I interferon
--
e129
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m138
0
infinite
0
--
LPS: TLR4: MAL
--
e13
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m14
0
infinite
0
--
Rig-1
--
e130
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m139
0
infinite
0
--
IL-1: IL-1R
--
e131
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m140
0
infinite
0
--
IL-1: IL-1R: MyD88
--
e132
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m141
0
infinite
0
--
dsRNA: TLR3: IRAK-2
--
e133
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m142
0
infinite
0
--
TLR ligand: TLR: TLR: MyD88: IRAK-1{activated}: IRAK-4
--
e134
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m143
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: Pellino1: Pellino2
--
e135
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m69
0
infinite
0
--
TRAF6{ub}
--
e136
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m145
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: Pellino1: Pellino2
--
e137
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m144
0
infinite
0
--
IRAK-1{p}{ub}: IRAK-2: IRAK-4: Pellino1: Pellino2
--
e138
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m146
0
infinite
0
--
IRAK-1{p}{ub}: IRAK-2: IRAK-4: Pellino1: Pellino2: IKK-gamma
--
e139
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m147
0
infinite
0
--
TLR1: TLR2
--
e14
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m15
0
infinite
0
--
IRAK-2: IRAK-4
--
e140
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m148
0
infinite
0
--
IRAK-1{p}{ub}: IRAK-2: IRAK-4: TRFA6
--
e141
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m149
0
infinite
0
--
TRIM20
--
e142
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m150
0
infinite
0
--
glucocorticoid receptor
--
e143
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m151
0
infinite
0
--
GRIP1: glucocorticoid receptor
--
e144
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m152
0
infinite
0
--
IRF-3{p}: GRIP1
--
e145
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m153
0
infinite
0
--
TAB1{ub}
--
e146
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m154
0
infinite
0
--
csml-variable:Double
m155
0
infinite
0
--
TLR6: TLR2
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m16
0
infinite
0
--
Lp: TLR1: TLR2
--
e16
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m17
0
infinite
0
--
csml-variable:Double
m18
0
infinite
0
--
Lp: TLR6: TLR2: MAL
--
e18
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m19
0
infinite
0
--
dsRNA: TLR3
--
e19
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m21
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
csml-variable:Double
m22
0
infinite
0
--
--
e21
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Endosome
--
--
--
csml-variable:Double
m23
0
infinite
0
--
--
e22
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeLumen
--
--
--
csml-variable:Double
m24
0
infinite
0
--
--
e23
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeMembrane
--
--
--
csml-variable:Double
m25
0
infinite
0
--
CpG motif: TLR9: TLR9
--
e24
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m26
0
infinite
0
--
csml-variable:Double
m27
0
infinite
0
--
csml-variable:Double
m28
0
infinite
0
--
iE-DAP: Nod1
--
e27
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m29
0
infinite
0
--
MDP: Nod2
--
e28
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m30
0
infinite
0
--
uric acid crystals
--
e29
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m31
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
MDP: Nalp3
--
e30
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m32
0
infinite
0
--
uric acid crystals: Nalp3
--
e31
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m33
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: TRFA6{ubK63}: Ubc13: Uev1: TAK1{activated}: TAB1: TAB2: MKK3
--
e32
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m34
0
infinite
0
--
asbestos
--
e33
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m35
0
infinite
0
--
asbestos: Nalp3
--
e34
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m36
0
infinite
0
--
ssRNA
--
e35
cso30:c:Rna
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m37
0
infinite
0
--
RIG-1
--
e36
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m38
0
infinite
0
--
csml-variable:Double
m39
0
infinite
0
--
beta-glucan
--
e38
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m40
0
infinite
0
--
beta-glucan: Dectin-1
--
e39
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m41
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
TLR ligand: TLR: TLR
--
e40
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m42
0
infinite
0
--
TLR ligand: TLR: TLR: MyD88: IRAK-1: IRAK-4: IRAK-2
--
e41
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m43
0
infinite
0
--
TLR ligand: TLR: TLR: MyD88: IRAK-1{activated}: IRAK-4
--
e42
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m44
0
infinite
0
--
TLR ligand: TLR: TLR: MyD88: IRAK-1: IRAK-4: IRAK-2{activated}
--
e43
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m45
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: TRFA6
--
e44
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m46
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4
--
e45
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m47
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: TRFA6{ubK63}: Ubc13: Uev1
--
e46
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m48
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: TRFA6: Ubc13: Uev1
--
e47
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m49
0
infinite
0
--
IRAK-1{p}: IRAK-4: TRFA6{ubK63}: Ubc13: Uev1: TAK1: TAB1: TAB2
--
e48
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m63
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: TRFA6{ubK63}: Ubc13: Uev1: TAK1{activated}: TAB1: TAB2
--
e49
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m64
0
infinite
0
--
TLR ligand
--
e5
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m6
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
TLR ligand: TLR
--
e6
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m11
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: TRFA6{ubK63}: Ubc13: Uev1: TAK1{activated}: TAB1: TAB2: IKK-alpha:IKK-beta:IKK-gamma
--
e63
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m65
0
infinite
0
--
IRAK-1{p}: IRAK-2: IRAK-4: TRFA6{ubK63}: Ubc13: Uev1: TAK1{activated}: TAB1: TAB2: MKK6
--
e64
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m66
0
infinite
0
--
NF-kappaB {activated}
--
e65
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m67
10
infinite
0
TRANSPATH | MO000000058 |
--
LPS: TLR4: MAL: MyD88
--
e68
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m72
0
infinite
0
--
Lp: TLR6: TLR2: MAL: MyD88
--
e69
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m73
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
LPS: TLR4: TRAM
--
e70
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m74
0
infinite
0
--
LPS: TLR4: TRAM: TRIF
--
e71
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m75
0
infinite
0
--
dsRNA: TLR3: TRIF
--
e72
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m76
0
infinite
0
--
LPS: TLR4
--
e73
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m77
0
infinite
0
--
LPS: TLR4: TRAM: TRIF: TRAF{activated}: TBK1
--
e74
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m78
0
infinite
0
--
dsRNA: TLR3: TRIF: TBK1
--
e75
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m79
0
infinite
0
--
LPS: TLR4: TRAM: TRIF: TRAF3
--
e76
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m80
0
infinite
0
--
LPS: TLR4: TRAM: TRIF: TRAF3{activated}
--
e77
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m81
0
infinite
0
--
LPS: TLR4: TRAM: TRIF: TRAF{activated}: TBK1{activated}
--
e78
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m82
0
infinite
0
--
dsRNA: TLR3: TRIF: TBK1{activated}
--
e79
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m83
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
MAL{membrane}
--
e80
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m84
0
infinite
0
--
TRAm{myristoylated}
--
e81
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m85
0
infinite
0
--
MAL{myristoylated}
--
e82
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m86
0
infinite
0
--
TRAM{membrane}
--
e83
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m87
0
infinite
0
--
TRAM{pS16}
--
e84
cso30:c:Protein
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m88
0
infinite
0
--
SARM
--
e85
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m89
0
infinite
0
--
JNK3: SARM
--
e86
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m90
0
infinite
0
--
TcpC
--
e87
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m91
0
infinite
0
--
TcpC: MyD88
--
e88
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m92
0
infinite
0
--
csml-variable:Double
m93
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
ATP: Nalp3
--
e90
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m94
0
infinite
0
--
csml-variable:Double
m95
0
infinite
0
--
silica: Nalp3
--
e92
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m96
0
infinite
0
--
potassium{extracellular}
--
e94
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m98
0
infinite
0
--
potassium
--
e95
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m99
0
infinite
0
--
R837
--
e96
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m100
0
infinite
0
--
Caspase-1
--
e97
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m101
10
infinite
0
TRANSPATH | MO000016828 |
--
R837: TLR7
--
e98
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m102
0
infinite
0
--
R837: TLR7: MyD88
--
e99
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m103
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m6*m3962*0.1
nodelay
--
0
PMID: 18631453, 15795223 In brief, the model currently used to describe initiation of signaling involves ligand-induced dimerization of TLRs, creating a TIR-TIR interface, which acts to recruit adapters via their TIR domains.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c30 : 1
m27*m4923*0.1
nodelay
--
0
PMID: 18631453, 17967410 NLRs that have been assigned functions include NOD1 and NOD2, which sense iE-DAP and MDP, respectively.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c297 : 1
stoichiometry:c296 : 1
m135*0.1
nodelay
--
0
PMID: 18631453 This leads to activation of STAT1 and, in turn, induction of SOCS1 and SOCS3, which act to block TLR signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c298 : 1
stoichiometry:c299 : 1
stoichiometry:c300 : 1
m1805*m45*0.1
nodelay
--
0
PMID: 18631453 The mechanism in both cases appears to be SHP1 binding to the kinase domain of IRAK-1 (which contains several phosphoaccepting tyrosines), where it inhibits its activity.
p102
p102
cso30:i:ME_UnknownDegradation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c301 : 1
stoichiometry:c302 : 1
stoichiometry:c303 : 1
stoichiometry:c304 : 1
m136*0.1
nodelay
--
0
PMID: 18631453, 18391954 This kinase activity is required for induction of proinflammatory cytokines, but is somehow inhibitory for induction of type I interferons, because autophosphoylation of IRAK1 leads to its degradation, allowing for increased production of type I interferons.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c307 : 1
stoichiometry:c305 : 1
m45*0.1
nodelay
--
0
PMID: 18631453, 18391954 This kinase activity is required for induction of proinflammatory cytokines, but is somehow inhibitory for induction of type I interferons, because autophosphoylation of IRAK1 leads to its degradation, allowing for increased production of type I interferons.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c308 : 1
stoichiometry:c306 : 1
1.0*0.1
nodelay
--
0
PMID: 18631453, 18391954 This kinase activity is required for induction of proinflammatory cytokines, but is somehow inhibitory for induction of type I interferons, because autophosphoylation of IRAK1 leads to its degradation, allowing for increased production of type I interferons.
p105
p105
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c309 : 1
stoichiometry:c310 : 1
stoichiometry:c311 : 1
m136*m138*0.1
nodelay
--
0
PMID: 18631453 Intriguingly, SHP1 promotes production of type I interferons by TLRs and also RIG-I.
p106
p106
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c313 : 1
stoichiometry:c314 : 1
stoichiometry:c315 : 1
stoichiometry:c312 : 1
m138*m139*m1805*0.1
nodelay
--
0
PMID: 18631453 Intriguingly, SHP1 promotes production of type I interferons by TLRs and also RIG-I.
p107
p107
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c320 : 1
stoichiometry:c324 : 1
stoichiometry:c321 : 1
m977*m82*0.1
nodelay
--
0
PMID: 18631453 In this case, SHP2 was shown to target TBK-1, the kinase that phosphorylates IRF3.
p108
p108
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c322 : 1
stoichiometry:c325 : 1
stoichiometry:c323 : 1
m977*m83*0.1
nodelay
--
0
PMID: 18631453 In this case, SHP2 was shown to target TBK-1, the kinase that phosphorylates IRF3.
p109
p109
cso30:i:ME_Translation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c329 : 1
stoichiometry:c330 : 1
stoichiometry:c328 : 1
m93217*m136*0.1
nodelay
--
0
PMID: 18631453 Although related, therefore, SHP1 and SHP2 have opposite effects. SHP1 promotes interferon-¦Â production in response to TLRs, whereas SHP2 is inhibitory.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c33 : 1
stoichiometry:c32 : 1
m4947*m28*0.1
nodelay
--
0
PMID: 18631453, 17967410 NLRs that have been assigned functions include NOD1 and NOD2, which sense iE-DAP and MDP, respectively.
p110
p110
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c332 : 1
stoichiometry:c335 : 1
stoichiometry:c331 : 1
m19324*0.1
nodelay
--
0
PMID: 18631453 SHP2 limits TLR3-induced production of proinflammatory cytokines and interferon-beta, without affecting TLR2 or TLR9 signaling.
p111
p111
cso30:i:ME_GeneExpression
cso30:i:CC_NuclearChromosome
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c333 : 1
stoichiometry:c336 : 1
stoichiometry:c334 : 1
m19324*0.1
nodelay
--
0
PMID: 18631453 SHP2 limits TLR3-induced production of proinflammatory cytokines and interferon-beta, without affecting TLR2 or TLR9 signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c337 : 1
stoichiometry:c338 : 1
stoichiometry:c339 : 1
m1572*m140*0.1
nodelay
--
0
PMID: 18631453 In IL-1 signaling, MyD88 is recruited to the receptor complex within seconds, where it stably associates.
p113
p113
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c340 : 1
stoichiometry:c341 : 1
stoichiometry:c342 : 1
m1569*m21*0.1
nodelay
--
0
PMID: 18631453 For TLR3, IRAK2 is directly recruited.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c353 : 1
stoichiometry:c354 : 1
m69*0.1
nodelay
--
0
PMID: 18631453 Importantly, their activity is greatly enhanced, at least in vitro, in response to phosphorylation by IRAK1 and IRAK4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c55 : 1
stoichiometry:c56 : 1
m43*0.1
nodelay
--
0
PMID: 18631453 It was shown that similar to IRAK1, IRAK2 was activated downstream of IRAK4.
p116
p116
cso30:i:ME_Ubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c346 : 1
stoichiometry:c347 : 1
stoichiometry:c348 : 1
m183*m1585*0.1
nodelay
--
0
PMID: 18631453 A20 is a key ubiquitin-editing enzyme that restricts TLR responses by regulating the ubiquitination of key signaling proteins such as Traf6.
p117
p117
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c349 : 1
stoichiometry:c350 : 1
stoichiometry:c351 : 1
stoichiometry:c352 : 1
m47*m19287*m19301*0.1
nodelay
--
0
pMID: 18631453, 17675297, 17997719 Two proteins, termed Pellino-1 and Pellino-3b, appear to be important in this process. These proteins were known to interact with IRAK-1, and recent studies indicate that similar to Traf6, they are E3 ligases.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c355 : 1
stoichiometry:c356 : 1
m144*0.1
nodelay
--
0
PMID: 18631453 The role of the kinase activity of IRAK1 and/or IRAK4 might therefore be at least initially to activate Pellinos, such that they can cause K63-linked polyubiquitination of IRAK1.
p119
p119
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c357 : 1
stoichiometry:c358 : 1
stoichiometry:c359 : 1
m146*m1593*0.1
nodelay
--
0
PMID: 18631453 Most interestingly, this recruits NEMO to IRAK1, with NEMO binding to polyubiquitin.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c35 : 1
stoichiometry:c36 : 1
m28*m86033*0.1
nodelay
--
0
PMID: 18631453, 15530394, 16407889, 18403674 In addition, Nalp3 (also called Cryopyrin of Nlrp3) senses multiple pathogens, pathogen products such as MDP, and products of damaged cells such as uric acid crystals and exogenous crystals such as asbestos.
p120
p120
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c360 : 1
stoichiometry:c362 : 1
stoichiometry:c363 : 1
stoichiometry:c361 : 1
m20*m34*0.1
nodelay
--
0
PMID: 18631453 These ultimately trigger NF-kappaB, p38, and ERK activation. PMID: 18631453, 18391954 It has been shown that SHP1 negatively regulates TLR-mediated production of proinflammatory cytokines by inhibiting activation of NF-kappaB and MAP kinases.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c318 : 1
stoichiometry:c364 : 1
m46*0.1
nodelay
--
0
PMID: 18631453 There is also evidence that TRAF6 ubiquitinates IRAK1.
p122
p122
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c389 : 1
stoichiometry:c367 : 1
m155*0.1
nodelay
--
0
PMID: 18631453, 18345001 In the second study, a protein termed TRIM30-alpha, which has a RING finger (often indicative of E3 ubiquitin ligase activity) was shown to limit TLR signaling by targeting TAB2 and TAB3, causing their degradation. This effect was not via the ubiquitin-proteasome pathway, however, but depended on lysosomal degradation.
p123
p123
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c388 : 1
stoichiometry:c368 : 1
m154*0.1
nodelay
--
0
PMID: 18631453, 18345001 In the second study, a protein termed TRIM30-alpha, which has a RING finger (often indicative of E3 ubiquitin ligase activity) was shown to limit TLR signaling by targeting TAB2 and TAB3, causing their degradation. This effect was not via the ubiquitin-proteasome pathway, however, but depended on lysosomal degradation.
p124
p124
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c372 : 1
stoichiometry:c371 : 1
m6069*0.1
nodelay
--
0
PMID: 18631453, 12391149, 16880258, 16380513 The mechanism was shown to involve induction of a phosphatase termed MKP-1 which dephosphorylates p38 and thereby inactivates it.
p125
p125
cso30:i:ME_Dephosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c373 : 1
stoichiometry:c375 : 1
stoichiometry:c374 : 1
m68*m94283*0.1
nodelay
--
0
PMID: 18631453, 12391149, 16880258, 16380513 The mechanism was shown to involve induction of a phosphatase termed MKP-1 which dephosphorylates p38 and thereby inactivates it.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c377 : 1
stoichiometry:c379 : 1
stoichiometry:c378 : 1
m151*m49366*0.1
nodelay
--
0
PMID: 18631453 GRIP1 is a protein that interacts with the glucocorticoid receptor.
p127
p127
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c380 : 1
stoichiometry:c381 : 1
stoichiometry:c383 : 1
stoichiometry:c382 : 1
m19324*m49366*0.1
nodelay
--
0
PMID: 18631453 A yeast two-hybrid screen isolated IRF3 as an interacting protein, and it was shown that GRIP1 was required for IRF3-mediated transactivation. PMID: 18631453, 16362036 Importantly the glucocorticoid receptor competed with IRF3 for GRIP1 and thereby blocked IRF3-mediated gene expression.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c384 : 1
stoichiometry:c385 : 1
m153*0.1
nodelay
--
0
PMID: 18631453, 16362036 Importantly the glucocorticoid receptor competed with IRF3 for GRIP1 and thereby blocked IRF3-mediated gene expression.
p129
p129
cso30:i:ME_Ubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c365 : 1
stoichiometry:c391 : 1
stoichiometry:c366 : 1
m1583*m150*0.1
nodelay
--
0
PMID: 18631453, 18345001 In the second study, a protein termed TRIM30-alpha, which has a RING finger (often indicative of E3 ubiquitin ligase activity) was shown to limit TLR signaling by targeting TAB2 and TAB3, causing their degradation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
m86033*m31*0.1
nodelay
--
0
PMID: 18631453, 15530394, 16407889, 18403674 In addition, Nalp3 (also called Cryopyrin of Nlrp3) senses multiple pathogens, pathogen products such as MDP, and products of damaged cells such as uric acid crystals and exogenous crystals such as asbestos.
p130
p130
cso30:i:ME_Ubiquitination
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c386 : 1
stoichiometry:c390 : 1
stoichiometry:c387 : 1
m6433*m150*0.1
nodelay
--
0
PMID: 18631453, 18345001 In the second study, a protein termed TRIM30-alpha, which has a RING finger (often indicative of E3 ubiquitin ligase activity) was shown to limit TLR signaling by targeting TAB2 and TAB3, causing their degradation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c41 : 1
stoichiometry:c42 : 1
m86033*m35*0.1
nodelay
--
0
PMID: 18631453, 15530394, 16407889, 18403674 In addition, Nalp3 (also called Cryopyrin of Nlrp3) senses multiple pathogens, pathogen products such as MDP, and products of damaged cells such as uric acid crystals and exogenous crystals such as asbestos.
p15
p15
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c44 : 1
stoichiometry:c45 : 1
m38*m37*0.1
nodelay
--
0
PMID: 18631453, 15208624, 12163569 The best-known RLR is RIG-I, which senses single-stranded RNA found in viruses, and the best known CLR is Dectin-1, which senses beta-glucan, found in fungal cell walls.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c46 : 1
stoichiometry:c48 : 1
stoichiometry:c47 : 1
m4193*m40*0.1
nodelay
--
0
PMID: 18631453, 15208624, 12163569 The best-known RLR is RIG-I, which senses single-stranded RNA found in viruses, and the best known CLR is Dectin-1, which senses beta-glucan, found in fungal cell walls.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c6 : 1
stoichiometry:c49 : 1
m11*0.1
nodelay
--
0
PMID: 18631453, 15795223 In brief, the model currently used to describe initiation of signaling involves ligand-induced dimerization of TLRs, creating a TIR-TIR interface, which acts to recruit adapters via their TIR domains.
p18
p18
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c51 : 1
stoichiometry:c52 : 1
stoichiometry:c53 : 1
stoichiometry:c343 : 1
stoichiometry:c54 : 1
m184*m12*m17258*m1569*0.1
nodelay
--
0
PMID: 18631453 This in turn leads to the recruitment of IRAK1 and IRAK4. PMID: 18631453 IRAK4 and IRAK1 (and probably IRAK2) are then recruited to MyD88.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c344 : 1
m143*0.1
nodelay
--
0
PMID: 18631453 IRAK4 then activates IRAK1, allowing IRAK1 to autophosphorylate.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c50 : 1
stoichiometry:c147 : 1
stoichiometry:c5 : 1
m1572*m42*0.1
nodelay
--
0
PMID: 18631453 MyD88 is the universal adaptor, used by all TLRs except TLR3, and acts to recruit the IRAK family of kinases. PMID: 18631453, 18327267 A uropathogenic strain of E. coli, termed CFT073, was then shown to have a TIR-domain-containing protein termed TIR-containing protein C (TcpC). The bacteria release this protein, which is somehow taken up by macrophages, where it interacts with MyD88 to prevent signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c60 : 1
stoichiometry:c61 : 1
m45*0.1
nodelay
--
0
PMID; 18631453 Both IRAK1 and IRAK4 then dissociate from MyD88, which remains in a complex with the activated receptor¡½this has been shown for IL-1RI and will most probably apply to the TLRs. PMID: 18631453 IRAK4 then phosphorylates IRAK1, and the kinases dissociate from MyD88.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c345 : 1
stoichiometry:c58 : 1
m44*0.1
nodelay
--
0
PMID: 18631453 IRAK4 then activates IRAK1, allowing IRAK1 to autophosphorylate.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c63 : 1
stoichiometry:c64 : 1
m47*m183*0.1
nodelay
--
0
PMID: 18631453 They in turn interact with TRAF6, which is an E3 ubiquitin ligase. PMID: 18631453 IRAK2 leads to K63-linked polyubiquitination of TRAF6, which serves as a platform to recruit TAK1. PMID: 18631453 IRAK1 has a similar role to IRAK2¡½it leads to K63-linked polyubiquitination of TRAF6 and TAK1 recruitment.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c65 : 1
stoichiometry:c66 : 1
m49*0.1
nodelay
--
0
PMID: 18361453 TRAF6 is then thought to autoubiquinate, attaching K63-polyubiquitin to itself. PMID: 18631453 IRAK2 leads to K63-linked polyubiquitination of TRAF6, which serves as a platform to recruit TAK1. PMID: 18631453 IRAK1 has a similar role to IRAK2¡½it leads to K63-linked polyubiquitination of TRAF6 and TAK1 recruitment.
p24
p24
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c69 : 1
stoichiometry:c71 : 1
stoichiometry:c70 : 1
m6443*m6446*m46*0.1
nodelay
--
0
PMID: 18631453, 11057907 The E2-conjugating complexes Ubc13 and Uev1a are also involved in this process.
p25
p25
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c67 : 1
stoichiometry:c73 : 1
stoichiometry:c74 : 1
stoichiometry:c75 : 1
stoichiometry:c72 : 1
m48*m1573*m1583*m6433*0.1
nodelay
--
0
PMID: 18631453 K63-polyubiquitin-TRAF6 can then recruit TAK1 in a complex with TAB2 and TAB3, which both contain nuclear zinc-finger motifs that interact with K63-polyubiquitin chains.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c77 : 1
m63*0.1
nodelay
--
0
PMID: 18631453 This somehow activates TAK1, which then couples to the IKK complex, which contains the scaffold protein NEMO and the kinase responsible for phosphorylation of I-kappaB, IKK2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c78 : 1
stoichiometry:c79 : 1
stoichiometry:c80 : 1
m64*m1637*0.1
nodelay
--
0
PMID: 18631453 This somehow activates TAK1, which then couples to the IKK complex, which contains the scaffold protein NEMO and the kinase responsible for phosphorylation of I-kappaB, IKK2.
p28
p28
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c81 : 1
stoichiometry:c83 : 1
stoichiometry:c82 : 1
m199*m65*0.1
nodelay
--
0
PMID: 18631453 This somehow activates TAK1, which then couples to the IKK complex, which contains the scaffold protein NEMO and the kinase responsible for phosphorylation of I-kappaB, IKK2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c84 : 1
stoichiometry:c87 : 1
stoichiometry:c86 : 1
m64*m1875*0.1
nodelay
--
0
PMID: 18631453 TAK1 also couples to MKK3-MKK6 and MKK7, the respective upstream kinases for p38 and JNK.
p3
p3
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m3961*m155666*0.1
nodelay
--
0
PMID: 18631453 The best characterized are TLR2, which in combination with TLR1 or TLR6 can recognize acylated lipopeptides; TLR3, which senses double-stranded RNA; TLR4, which senses LPS; and TLR9, which senses hypomethylated CpG motifs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c88 : 1
stoichiometry:c89 : 1
m64*m3613*0.1
nodelay
--
0
PMID: 18631453 TAK1 also couples to MKK3-MKK6 and MKK7, the respective upstream kinases for p38 and JNK.
p31
p31
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c90 : 1
stoichiometry:c92 : 1
stoichiometry:c249 : 1
stoichiometry:c275 : 1
stoichiometry:c316 : 1
stoichiometry:c91 : 1
m5*m190*m113*0.1
nodelay
--
0
PMID: 18631453 These ultimately trigger NF-kappaB, p38, and ERK activation. PMID: 18631453 It might involve activation of PI3 kinase, which via Akt has been shown to block NF-kappaB activation by TLR4. PMID: 18631453, 18391954 It has been shown that SHP1 negatively regulates TLR-mediated production of proinflammatory cytokines by inhibiting activation of NF-kappaB and MAP kinases.
p32
p32
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c94 : 1
stoichiometry:c95 : 1
m146*0.1
nodelay
--
0
PMID: 18631453 Ultimately, both IRAK1 and the Pellinos (which also undergo ubiquitination) are probably degraded to terminate the signal.
p33
p33
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c96 : 1
stoichiometry:c97 : 1
stoichiometry:c319 : 1
stoichiometry:c98 : 1
m66*m70*0.1
nodelay
--
0
PMID: 18631453 These ultimately trigger NF-kappaB, p38, and ERK activation. PMID: 18631453, 18391954 It has been shown that SHP1 negatively regulates TLR-mediated production of proinflammatory cytokines by inhibiting activation of NF-kappaB and MAP kinases.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c99 : 1
stoichiometry:c100 : 1
stoichiometry:c148 : 1
stoichiometry:c104 : 1
m14*m1572*0.1
nodelay
--
0
PMID: 18631453 MyD88 adaptor-like (Mal, also called TIRAP) is recruited by TLR2 and TLR4, and so far its main function appears to be to subsequently stabilize MyD88 in the complex, acting as a bridge. PMID: 18631453, 18327267 A uropathogenic strain of E. coli, termed CFT073, was then shown to have a TIR-domain-containing protein termed TIR-containing protein C (TcpC). The bacteria release this protein, which is somehow taken up by macrophages, where it interacts with MyD88 to prevent signaling.
p35
p35
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c101 : 1
stoichiometry:c102 : 1
stoichiometry:c149 : 1
stoichiometry:c103 : 1
m1572*m19*0.1
nodelay
--
0
PMID: 18631453 MyD88 adaptor-like (Mal, also called TIRAP) is recruited by TLR2 and TLR4, and so far its main function appears to be to subsequently stabilize MyD88 in the complex, acting as a bridge. PMID: 18631453, 18327267 A uropathogenic strain of E. coli, termed CFT073, was then shown to have a TIR-domain-containing protein termed TIR-containing protein C (TcpC). The bacteria release this protein, which is somehow taken up by macrophages, where it interacts with MyD88 to prevent signaling.
p36
p36
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c105 : 1
stoichiometry:c140 : 1
stoichiometry:c107 : 1
m77*m88*0.1
nodelay
--
0
PMID: 18631453 Trif is used by TLR3 and also TLR4, but in the case of TLR4 another bridging adaptor is needed, Tram. PMID: 18631453 TLR4 in endosomes recruits TRAM and TRIF, leading to TRAF3 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c112 : 1
stoichiometry:c113 : 1
m18998*m21*0.1
nodelay
--
0
PMID: 18631453 Trif is used by TLR3 and also TLR4, but in the case of TLR4 another bridging adaptor is needed, Tram.
p38
p38
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c108 : 1
stoichiometry:c110 : 1
stoichiometry:c109 : 1
m74*m18998*0.1
nodelay
--
0
PMID: 18631453 Trif is used by TLR3 and also TLR4, but in the case of TLR4 another bridging adaptor is needed, Tram. PMID: 18631453 TLR4 in endosomes recruits TRAM and TRIF, leading to TRAF3 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c114 : 1
stoichiometry:c115 : 1
m80*0.1
nodelay
--
0
PMID: 18631453 TLR4 in endosomes recruits TRAM and TRIF, leading to TRAF3 activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c11 : 1
stoichiometry:c130 : 1
stoichiometry:c12 : 1
m13*m84*0.1
nodelay
--
0
PMID: 18631453 MyD88 adaptor-like (Mal, also called TIRAP) is recruited by TLR2 and TLR4, and so far its main function appears to be to subsequently stabilize MyD88 in the complex, acting as a bridge.
p40
p40
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c125 : 1
stoichiometry:c326 : 1
stoichiometry:c376 : 1
stoichiometry:c126 : 1
m78*0.1
nodelay
--
0
PMID: 18631453, 18222170, 18297073 Trif leads to IRF3 activation via recruitment of the kinase TBK-1, and this signal, in the case of both TLR3 and TLR4, comes from the endosome, with TLR4 trafficking there after LPS recognition. PMID: 18631453 In this case, SHP2 was shown to target TBK-1, the kinase that phosphorylates IRF3. PMID: 18631453, 18356163 In addition, another study has shown that activation of TBK-1, the upstream kinase for IRF3, is inhibited by glucocorticoids, again pointing to a more general mechanism rather than inhibition of TLR4 specifically.
p41
p41
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c121 : 1
stoichiometry:c327 : 1
stoichiometry:c128 : 1
m79*0.1
nodelay
--
0
PMID: 18631453, 18222170, 18297073 Trif leads to IRF3 activation via recruitment of the kinase TBK-1, and this signal, in the case of both TLR3 and TLR4, comes from the endosome, with TLR4 trafficking there after LPS recognition. PMID: 18631453 In this case, SHP2 was shown to target TBK-1, the kinase that phosphorylates IRF3.
p42
p42
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c116 : 1
stoichiometry:c123 : 1
stoichiometry:c122 : 1
m75*m1872*0.1
nodelay
--
0
PMID: 18631453 TLR4 will then traffic to endosomes, where TRAM is now engaged, recruiting TRIF, which in turn recruits TRAF3 to activate TBK-1.
p43
p43
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c118 : 1
stoichiometry:c119 : 1
m81*m3902*0.1
nodelay
--
0
PMID: 18631453, 18222170, 18297073 Trif leads to IRF3 activation via recruitment of the kinase TBK-1, and this signal, in the case of both TLR3 and TLR4, comes from the endosome, with TLR4 trafficking there after LPS recognition.
p44
p44
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c120 : 1
stoichiometry:c124 : 1
stoichiometry:c127 : 1
m3902*m76*0.1
nodelay
--
0
PMID: 18631453, 18222170, 18297073 Trif leads to IRF3 activation via recruitment of the kinase TBK-1, and this signal, in the case of both TLR3 and TLR4, comes from the endosome, with TLR4 trafficking there after LPS recognition.
p45
p45
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c129 : 1
stoichiometry:c106 : 1
stoichiometry:c139 : 1
m1629*m87*0.1
nodelay
--
0
PMID: 18631453, 16757566 Phosphorylation of TRAM on serine 16 by protein kinase C-epsilon is required for this process and may be required for endosomal trafficking or displacement of Mal-MyD88 from the complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c136 : 1
stoichiometry:c10 : 1
m86*0.1
nodelay
--
0
PIMD: 18631453, 16751103, 16603631 Mal has a phosphatidylinositol-4,5-bisphosphase (PIP2) binding domain that localizes it to the plasma membrane, whereas TRAM is myristoylated for the same reason.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c133 : 1
stoichiometry:c134 : 1
m19005*0.1
nodelay
--
0
PIMD: 18631453, 16751103, 16603631 Mal has a phosphatidylinositol-4,5-bisphosphase (PIP2) binding domain that localizes it to the plasma membrane, whereas TRAM is myristoylated for the same reason.
p48
p48
cso30:i:ME_Myristoylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c135 : 1
stoichiometry:c131 : 1
m43675*m290229*0.1
nodelay
--
0
PIMD: 18631453, 16751103, 16603631 Mal has a phosphatidylinositol-4,5-bisphosphase (PIP2) binding domain that localizes it to the plasma membrane, whereas TRAM is myristoylated for the same reason.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c138 : 1
m85*0.1
nodelay
--
0
PIMD: 18631453, 16751103, 16603631 Mal has a phosphatidylinositol-4,5-bisphosphase (PIP2) binding domain that localizes it to the plasma membrane, whereas TRAM is myristoylated for the same reason.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c15 : 1
stoichiometry:c18 : 1
stoichiometry:c16 : 1
m16*m2549*0.1
nodelay
--
0
PMID: 18631453 The best characterized are TLR2, which in combination with TLR1 or TLR6 can recognize acylated lipopeptides; TLR3, which senses double-stranded RNA; TLR4, which senses LPS; and TLR9, which senses hypomethylated CpG motifs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c141 : 1
stoichiometry:c142 : 1
stoichiometry:c143 : 1
m2570*m89*0.1
nodelay
--
0
PMID: 18631453, 17724133 It has also been shown to be expressed in neurons, where it interacts with the MAP kinase JNK3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c144 : 1
stoichiometry:c145 : 1
stoichiometry:c146 : 1
m91*m1572*0.1
nodelay
--
0
PMID: 18631453, 18327267 A uropathogenic strain of E. coli, termed CFT073, was then shown to have a TIR-domain-containing protein termed TIR-containing protein C (TcpC). The bacteria release this protein, which is somehow taken up by macrophages, where it interacts with MyD88 to prevent signaling.
p52
p52
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c150 : 1
stoichiometry:c155 : 1
stoichiometry:c151 : 1
m93364*m67*0.1
nodelay
--
0
PMID: 18631453 A clear-cut example of this ¡Ètwo-signal¡É approach is the ability of TLRs to induce pro-IL-1beta production, but without causing processing to the mature cytokine, as shown in Figure 1.
p53
p53
cso30:i:ME_ProteinCleavage
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c152 : 1
stoichiometry:c154 : 1
stoichiometry:c153 : 1
m4012*m1765*0.1
nodelay
--
0
PMID: 18631453 Various stimuli act via Nalp3 to activate caspase-1, which processes the pro-IL-1beta protein into mature IL-1beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c156 : 1
stoichiometry:c157 : 1
stoichiometry:c158 : 1
m86033*m93*0.1
nodelay
--
0
PMID: 18631453, 15530394, 16407889, 18403674 Nalp3 is a key component of an important caspase-1-containing inflammasome and is activated by various pathogens; such substances as ATP, MDP and, most recently, other types of crystals such as asbestos and silica.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c159 : 1
stoichiometry:c160 : 1
stoichiometry:c161 : 1
m86033*m95*0.1
nodelay
--
0
PMID: 18631453, 15530394, 16407889, 18403674 Nalp3 is a key component of an important caspase-1-containing inflammasome and is activated by various pathogens; such substances as ATP, MDP and, most recently, other types of crystals such as asbestos and silica.
p56
p56
cso30:i:ME_Translocation
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c164 : 1
stoichiometry:c166 : 1
stoichiometry:c167 : 1
stoichiometry:c165 : 1
m99*m39857*m37969*0.1
nodelay
--
0
PMID: 18631453, 17433728 The mechanism of Nalp3 activation has been shown to involve a potassium efflux, mediated by the P2X7 receptor in combination with the ion channel pannexin-1.
p57
p57
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c162 : 1
stoichiometry:c168 : 1
stoichiometry:c169 : 1
stoichiometry:c170 : 1
stoichiometry:c163 : 1
m86033*m37969*m39857*m1063*0.1
nodelay
--
0
PMID: 18631453, 17433728 The mechanism of Nalp3 activation has been shown to involve a potassium efflux, mediated by the P2X7 receptor in combination with the ion channel pannexin-1. PMID: 18631453 It also appears to involve reactive oxygen species (ROS) generated by the NADPH oxidase, although how the potassium efflux or ROS generation leads to Nalp3 activation is not known.
p58
p58
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c171 : 1
stoichiometry:c176 : 1
stoichiometry:c175 : 1
stoichiometry:c174 : 1
m101*m155666*m94*0.1
nodelay
--
0
PMID: 18631453 TLR ligands such as LPS or the TLR7 ligand R837 also modulate the inflammasome, enabling ATP to activate caspase-1 via Nalp3.
p59
p59
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c172 : 1
stoichiometry:c206 : 1
stoichiometry:c173 : 1
m5783*m33*0.1
nodelay
--
0
PMID: 18631453 It also appears to involve reactive oxygen species (ROS) generated by the NADPH oxidase, although how the potassium efflux or ROS generation leads to Nalp3 activation is not known. PMID: 18631453 Uric acid and asbestos have been shown to activate NADPH-oxidase-generating reactive oxygen species (ROS), which are also required for Nalp3 activation, although again a mechanism is missing.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c17 : 1
stoichiometry:c14 : 1
m15*m2549*0.1
nodelay
--
0
PMID: 18631453 The best characterized are TLR2, which in combination with TLR1 or TLR6 can recognize acylated lipopeptides; TLR3, which senses double-stranded RNA; TLR4, which senses LPS; and TLR9, which senses hypomethylated CpG motifs.
p60
p60
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c177 : 1
stoichiometry:c179 : 1
stoichiometry:c180 : 1
stoichiometry:c178 : 1
m101*m94*m100*0.1
nodelay
--
0
PMID: 18631453 TLR ligands such as LPS or the TLR7 ligand R837 also modulate the inflammasome, enabling ATP to activate caspase-1 via Nalp3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c181 : 1
stoichiometry:c182 : 1
stoichiometry:c183 : 1
m1572*m102*0.1
nodelay
--
0
PMID: 18631453 TLRs such as TLR4 and TLR7 activate the standard signaling pathway via MyD88 and NF-kappaB to induce pro-IL-1beta mRNA.
p62
p62
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c184 : 1
stoichiometry:c186 : 1
stoichiometry:c317 : 1
stoichiometry:c185 : 1
m5*m103*0.1
nodelay
--
0
PMID: 18631453 TLRs such as TLR4 and TLR7 activate the standard signaling pathway via MyD88 and NF-kappaB to induce pro-IL-1beta mRNA. PMID: 18631453, 18391954 It has been shown that SHP1 negatively regulates TLR-mediated production of proinflammatory cytokines by inhibiting activation of NF-kappaB and MAP kinases.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c187 : 1
stoichiometry:c188 : 1
m67*0.1
nodelay
--
0
PMID: 18631453 TLRs such as TLR4 and TLR7 activate the standard signaling pathway via MyD88 and NF-kappaB to induce pro-IL-1beta mRNA.
p64
p64
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c189 : 1
stoichiometry:c191 : 1
stoichiometry:c190 : 1
m183*m72*0.1
nodelay
--
0
PMID: 18631453 TLR4 in the plasma membrane engages with Mal and subsequently MyD88, for NF-kappaB activation via TRAF6.
p65
p65
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c192 : 1
stoichiometry:c194 : 1
stoichiometry:c276 : 1
stoichiometry:c193 : 1
m5*m104*0.1
nodelay
--
0
PMID: 18631453 TLR4 in the plasma membrane engages with Mal and subsequently MyD88, for NF-kappaB activation via TRAF6. PMID: 18631453 It might involve activation of PI3 kinase, which via Akt has been shown to block NF-kappaB activation by TLR4.
p66
p66
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c195 : 1
stoichiometry:c198 : 1
stoichiometry:c199 : 1
m32*m101*0.1
nodelay
--
0
PMID: 18631453 Various stimuli act via Nalp3 to activate caspase-1, which processes the pro-IL-1beta protein into mature IL-1beta. These stimuli include ATP, MDP, uric acid, and asbestos.
p67
p67
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c196 : 1
stoichiometry:c200 : 1
stoichiometry:c201 : 1
m33*m101*0.1
nodelay
--
0
PMID: 18631453 Various stimuli act via Nalp3 to activate caspase-1, which processes the pro-IL-1beta protein into mature IL-1beta. These stimuli include ATP, MDP, uric acid, and asbestos.
p68
p68
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c197 : 1
stoichiometry:c202 : 1
stoichiometry:c203 : 1
m36*m101*0.1
nodelay
--
0
PMID: 18631453 Various stimuli act via Nalp3 to activate caspase-1, which processes the pro-IL-1beta protein into mature IL-1beta. These stimuli include ATP, MDP, uric acid, and asbestos.
p69
p69
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c204 : 1
stoichiometry:c207 : 1
stoichiometry:c205 : 1
m5783*m36*0.1
nodelay
--
0
PMID: 18631453 It also appears to involve reactive oxygen species (ROS) generated by the NADPH oxidase, although how the potassium efflux or ROS generation leads to Nalp3 activation is not known. PMID: 18631453 Uric acid and asbestos have been shown to activate NADPH-oxidase-generating reactive oxygen species (ROS), which are also required for Nalp3 activation, although again a mechanism is missing.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c21 : 1
stoichiometry:c132 : 1
stoichiometry:c20 : 1
m18*m84*0.1
nodelay
--
0
PMID: 18631453 MyD88 adaptor-like (Mal, also called TIRAP) is recruited by TLR2 and TLR4, and so far its main function appears to be to subsequently stabilize MyD88 in the complex, acting as a bridge.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c208 : 1
stoichiometry:c209 : 1
m105*0.1
nodelay
--
0
PMID: 18631453 TAM receptors in a complex with IFNAR1 induce SOCS1, which inhibits TLR4 by targeting Mal, and SOCS3, which inhibits TRAF3 and TRAF6.
p71
p71
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c210 : 1
stoichiometry:c216 : 1
stoichiometry:c211 : 1
m106*m72*0.1
nodelay
--
0
PMID: 18631453, 9151903 Notably, the tyrosine kinases Src, Hck, and Lyn have been shown to be activated by TLR4, although their exact role is uncertain because a hck, fyn, lyn triple-deficient mouse was normal for TLR4 signaling.
p72
p72
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c212 : 1
stoichiometry:c217 : 1
stoichiometry:c213 : 1
m751*m72*0.1
nodelay
--
0
PMID: 18631453, 9151903 Notably, the tyrosine kinases Src, Hck, and Lyn have been shown to be activated by TLR4, although their exact role is uncertain because a hck, fyn, lyn triple-deficient mouse was normal for TLR4 signaling.
p73
p73
cso30:i:ME_UnknownActivation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c214 : 1
stoichiometry:c218 : 1
stoichiometry:c215 : 1
m128*m72*0.1
nodelay
--
0
PMID: 18631453, 9151903 Notably, the tyrosine kinases Src, Hck, and Lyn have been shown to be activated by TLR4, although their exact role is uncertain because a hck, fyn, lyn triple-deficient mouse was normal for TLR4 signaling.
p74
p74
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c219 : 1
stoichiometry:c220 : 1
stoichiometry:c221 : 1
m26*m367*0.1
nodelay
--
0
PMID: 18631453, 15849198, 17932028, 18276597 Btk is recruited to both TLR4 and TLR9 and has been shown to be involved in the pathway leading to enhanced phosphorylation of the p65 subunit of NF-kappaB on serine 536, which is required for p65 to promote gene expression.
p75
p75
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c223 : 1
stoichiometry:c224 : 1
stoichiometry:c222 : 1
m367*m13*0.1
nodelay
--
0
PMID: 18631453, 15849198, 17932028, 18276597 Btk is recruited to both TLR4 and TLR9 and has been shown to be involved in the pathway leading to enhanced phosphorylation of the p65 subunit of NF-kappaB on serine 536, which is required for p65 to promote gene expression.
p76
p76
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c225 : 1
stoichiometry:c227 : 1
stoichiometry:c228 : 1
m110*m1617*0.1
nodelay
--
0
PMID: 18631453, 15849198, 17932028, 18276597 Btk is recruited to both TLR4 and TLR9 and has been shown to be involved in the pathway leading to enhanced phosphorylation of the p65 subunit of NF-kappaB on serine 536, which is required for p65 to promote gene expression.
p77
p77
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c226 : 1
stoichiometry:c229 : 1
stoichiometry:c230 : 1
m111*m1617*0.1
nodelay
--
0
PMID: 18631453, 15849198, 17932028, 18276597 Btk is recruited to both TLR4 and TLR9 and has been shown to be involved in the pathway leading to enhanced phosphorylation of the p65 subunit of NF-kappaB on serine 536, which is required for p65 to promote gene expression.
PMID: 18631453, 18276597 In B cells, Btk is required for TLR9-induced proliferation and IL-10 production.
p79
p79
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c233 : 1
stoichiometry:c234 : 1
stoichiometry:c232 : 1
m110*m94230*0.1
nodelay
--
0
PMID: 18631453, 18276597 In B cells, Btk is required for TLR9-induced proliferation and IL-10 production.
p8
p8
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m119368*m3965*0.1
nodelay
--
0
PMID: 18631453 TLR3, which senses double-stranded RNA.
p80
p80
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c236 : 1
stoichiometry:c237 : 1
stoichiometry:c235 : 1
m94230*m111*0.1
nodelay
--
0
PMID: 18631453, 17082638 Btk is also required for IL-10 induction by TLR4 in macrophages.
p81
p81
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c238 : 1
stoichiometry:c240 : 1
stoichiometry:c239 : 1
m20*m367*0.1
nodelay
--
0
PMID: 18631453 There is a role in TNF production, however, which was shown to be due to Btk's being required for p38 activation, which then stabilizes TNF but not IL-6 mRNA.
p82
p82
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c243 : 1
stoichiometry:c242 : 1
stoichiometry:c241 : 1
m367*m72*0.1
nodelay
--
0
PMID: 18631453, 16439361, 18070880 One substrate is Mal, which undergoes phosphorylation by Btk on Tyr-86 and Tyr-106.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c244 : 1
stoichiometry:c245 : 1
stoichiometry:c246 : 1
m1906*m113*0.1
nodelay
--
0
PMID: 18631453, 16415872 This event is required for Mal to signal NF-kappaB activation but, in addition, is involved in the ultimate degradation of Mal via the recruitment of suppressor of cytokine signaling 1 (SOCS1).
p84
p84
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c247 : 1
stoichiometry:c248 : 1
stoichiometry:c250 : 1
m112*0.1
nodelay
--
0
PMID: 18631453, 16415872 This event is required for Mal to signal NF-kappaB activation but, in addition, is involved in the ultimate degradation of Mal via the recruitment of suppressor of cytokine signaling 1 (SOCS1).
p85
p85
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c251 : 1
stoichiometry:c253 : 1
stoichiometry:c252 : 1
m115*m1066*0.1
nodelay
--
0
PMID: 18631453 The tyrosine kinase Syk plays a key role in DAP12 activation, phosphorylating tyrosine residues, and allowing for the recruitment of SH2-domain-containing proteins such as the p85-p110 dimer of PI3 kinase and phospholipase Cgamma.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c254 : 1
stoichiometry:c255 : 1
stoichiometry:c256 : 1
m116*m12175*0.1
nodelay
--
0
PMID: 18631453 The tyrosine kinase Syk plays a key role in DAP12 activation, phosphorylating tyrosine residues, and allowing for the recruitment of SH2-domain-containing proteins such as the p85-p110 dimer of PI3 kinase and phospholipase Cgamma.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c257 : 1
stoichiometry:c259 : 1
stoichiometry:c258 : 1
m116*m119*0.1
nodelay
--
0
PMID: 18631453 The tyrosine kinase Syk plays a key role in DAP12 activation, phosphorylating tyrosine residues, and allowing for the recruitment of SH2-domain-containing proteins such as the p85-p110 dimer of PI3 kinase and phospholipase Cgamma.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c260 : 1
stoichiometry:c262 : 1
stoichiometry:c261 : 1
m120*m115*0.1
nodelay
--
0
PMID: 1831453 At first, this seemed counterintuitive, because ITAM-containing proteins that couple to receptors had been shown to activate signaling pathways leading to inflammatory cytokine production, such as DAP12, which couples to the coreceptor TREM-1.
p89
p89
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c263 : 1
stoichiometry:c264 : 1
stoichiometry:c265 : 1
m3961*m121*0.1
nodelay
--
0
PMID: 18631453 The effect here appears to be proximity dependent¡½the antibody binds to TLR4 and the Fc portion binds to CD32A, bringing it into close proximity to TLR4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c26 : 1
stoichiometry:c27 : 1
m19828*m22*0.1
nodelay
--
0
PMID: 18631453 The best characterized are TLR2, which in combination with TLR1 or TLR6 can recognize acylated lipopeptides; TLR3, which senses double-stranded RNA; TLR4, which senses LPS; and TLR9, which senses hypomethylated CpG motifs. PMID: 18631453, 17572678 In the case of TLR9, it has been shown that a pre-exising dimer occurs, which presumably ¡Ètightens¡É upon ligand binding to create a new conformation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c266 : 1
stoichiometry:c267 : 1
stoichiometry:c268 : 1
m122*m123*0.1
nodelay
--
0
PMID: 18631453 The effect here appears to be proximity dependent¡½the antibody binds to TLR4 and the Fc portion binds to CD32A, bringing it into close proximity to TLR4.
p91
p91
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c269 : 1
stoichiometry:c271 : 1
stoichiometry:c270 : 1
m125*m124*0.1
nodelay
--
0
PMID: 18631453 It might involve activation of PI3 kinase, which via Akt has been shown to block NF-kappaB activation by TLR4.
p92
p92
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c272 : 1
stoichiometry:c274 : 1
stoichiometry:c273 : 1
m127*m126*0.1
nodelay
--
0
PMID: 18631453 It might involve activation of PI3 kinase, which via Akt has been shown to block NF-kappaB activation by TLR4.
p93
p93
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c277 : 1
stoichiometry:c279 : 1
stoichiometry:c278 : 1
m119*m124*0.1
nodelay
--
0
PMID: 18631453 Alternatively, because CD32A can activate phospholipase C-gamma, a depletion in PIP2 by this enzyme might lead to Mal's dissociation from the plasma membrane.
p94
p94
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c281 : 1
stoichiometry:c280 : 1
1.0*0.1
nodelay
--
0
PMID: 18631453 Alternatively, because CD32A can activate phospholipase C-gamma, a depletion in PIP2 by this enzyme might lead to Mal's dissociation from the plasma membrane.
p95
p95
cso30:i:ME_Dissociation
cso30:i:CC_Cytoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c282 : 1
stoichiometry:c284 : 1
stoichiometry:c283 : 1
m84*m119*0.1
nodelay
--
0
PMID: 18631453 Alternatively, because CD32A can activate phospholipase C-gamma, a depletion in PIP2 by this enzyme might lead to Mal's dissociation from the plasma membrane.
p96
p96
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c285 : 1
stoichiometry:c286 : 1
stoichiometry:c287 : 1
m131*m6039*0.1
nodelay
--
0
PMID: 18631453 Gas6 binds all three, although with different affinities.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c288 : 1
stoichiometry:c290 : 1
stoichiometry:c289 : 1
m133*m132*0.1
nodelay
--
0
PMID: 18631453 The ligands for the TAM receptors Gas6 and Protein S activate a signaling pathway via the R1 subunit of the type I interferon receptor, which has been shown to occur in a complex with Axl.
p98
p98
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c291 : 1
stoichiometry:c293 : 1
stoichiometry:c292 : 1
m1357*m134*0.1
nodelay
--
0
PMID: 18631453 This leads to activation of STAT1 and, in turn, induction of SOCS1 and SOCS3, which act to block TLR signaling.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c295 : 1
stoichiometry:c294 : 1
m135*0.1
nodelay
--
0
PMID: 18631453 This leads to activation of STAT1 and, in turn, induction of SOCS1 and SOCS3, which act to block TLR signaling.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--